Sorafenib discontinuation due to toxicity: A literature-based meta-analysis and meta-regression analysis of 18 randomized controlled trials in solid and hematologic malignancies.
Pharmacogenetic factors predicting the need for a higher dose of imatinib. Results: 29 SNPs were detected in the case-cohort population, 8 of which were analyzed in all 568 pts. IVS14+1G>A, 2846A>T, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback